EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Real-world use patterns, effectiveness, and tolerability of sacituzumab govitecan for second-line and later-line treatment of metastatic triple-negative breast cancer in the United States

Kevin Kalinsky, Laura Spring, Clinton Yam, Manali Ajay Bhave, Ioanna Ntalla, Catherine Lai, Nikoleta Sjekloca, Brian Stwalley, Michael Stokes, Aliki Taylor, Rita Nanda

Breast Cancer Research and Treatment · 2024

DOI: 10.1007/s10549-024-07412-9 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Breast Cancer Research and Treatment, 2024. Verfasst von Kevin Kalinsky und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Winship Cancer Institute, Emory University, 1365 Clifton Road Northeast, Bldg C, Fl 2, Atlanta, GA, 30322, USA. kevin…. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Antibodies, Monoclonal, Humanized, Camptothecin, Immunoconjugates. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gilead Sciences, Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Patients with metastatic triple-negative breast cancer (mTNBC) have poor prognosis and limited treatment options. Sacituzumab govitecan (SG), a Trop-2–directed antibody–drug conjugate, is approved for patients with mTNBC who have received ≥ 2 systemic therapies (≥ 1 in the metastatic setting) based on the ASCENT study (NCT02574455). The current study describes real-world SG use and outcomes in patients with mTNBC in the United States.

Methods

This retrospective, observational study included adult patients with mTNBC from the ConcertAI Patient360™ database who received SG in the second line (2L) and later from April 2020 to May 2022. SG use patterns, effectiveness, and tolerability are described.

Results

This analysis included 230 patients (median age 60 years, 26% Black, 17% with ECOG performance status ≥ 2, 66% in community settings; median of 2 prior lines of treatment in the metastatic setting); median follow-up was 7.2 months. Median (95% CI) real-world overall survival was 10.0 (8.3–11.1) months for all patients and 13.9 (9.8-not estimable) months in the 2L subgroup (n = 77). Granulocyte-colony stimulating factor (G-CSF) was administered concomitantly with SG in 134 (58%) patients; 35 (15%) received G-CSF for the first time. Median (IQR) time from SG start to G-CSF use was 8.5 (8.0–29.0) days. Seventeen (7%) patients discontinued SG due to toxicity.

Conclusions

Using a real-world, ethnically diverse population of patients with mTNBC presenting with poor prognosis, these data reinforced the findings from ASCENT. In routine clinical practice, SG is an effective treatment in the 2L setting, consistent with treatment guidelines.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsAntibodies, Monoclonal, HumanizedCamptothecinImmunoconjugatesHumansMiddle AgedFemaleRetrospective StudiesAgedUnited StatesAdultNeoplasm MetastasisTreatment OutcomeAged, 80 and over

Stichwörter der Autor:innen

MetastaticReal-world clinical outcomesSacituzumab govitecanSecond-lineTreatment patternsTriple-negative breast cancer

Substanzen

sacituzumab govitecanAntibodies, Monoclonal, HumanizedCamptothecinImmunoconjugates

Autor:innen und Institutionen

  • Department of Medical Oncology, Winship Cancer Institute, Emory University, 1365 Clifton Road Northeast, Bldg C, Fl 2, Atlanta, GA, 30322, USA. kevin.michael.kalinsky@emory.edu.
  • Division of Hematology/Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA.
  • Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Breast Oncology Program, Winship Cancer Institute, Emory University, Atlanta, GA, USA.
  • Real-World Evidence, Gilead Sciences Europe Ltd., Stockley Park, UK.
  • Clinical Development, Gilead Sciences, Inc., Foster City, CA, USA.

Förderung

  • Gilead Sciences, Inc.

Zitieren

APA

Kalinsky, K., Spring, L., Yam, C., Bhave, M. A., Ntalla, I., Lai, C., Sjekloca, N., Stwalley, B., Stokes, M., Taylor, A., & Nanda, R. (2024). Real-world use patterns, effectiveness, and tolerability of sacituzumab govitecan for second-line and later-line treatment of metastatic triple-negative breast cancer in the United States. Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-024-07412-9

Vancouver

Kalinsky K, Spring L, Yam C, Bhave MA, Ntalla I, Lai C, et al. Real-world use patterns, effectiveness, and tolerability of sacituzumab govitecan for second-line and later-line treatment of metastatic triple-negative breast cancer in the United States. Breast Cancer Research and Treatment. 2024. doi:10.1007/s10549-024-07412-9

BibTeX
@article{Kalinsky2024,
  author = {Kalinsky, Kevin and Spring, Laura and Yam, Clinton and Bhave, Manali Ajay and Ntalla, Ioanna and Lai, Catherine and Sjekloca, Nikoleta and Stwalley, Brian and Stokes, Michael and Taylor, Aliki and Nanda, Rita},
  title = {Real-world use patterns, effectiveness, and tolerability of sacituzumab govitecan for second-line and later-line treatment of metastatic triple-negative breast cancer in the United States},
  journal = {Breast Cancer Research and Treatment},
  year = {2024},
  doi = {10.1007/s10549-024-07412-9}
}
Kostenlos starten →